Astellas Pharma (OTCMKTS:ALPMY) Upgraded at Zacks Research

Zacks Research upgraded shares of Astellas Pharma (OTCMKTS:ALPMY) from a hold rating to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

Separately, Sanford C. Bernstein cut shares of Astellas Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Astellas Pharma currently has an average rating of “Buy”.

Astellas Pharma Stock Performance

Shares of OTCMKTS ALPMY opened at $11.49 on Tuesday. The firm’s 50 day moving average price is $10.61 and its 200-day moving average price is $9.96. Astellas Pharma has a 52-week low of $8.37 and a 52-week high of $12.73. The company has a current ratio of 1.13, a quick ratio of 0.85 and a debt-to-equity ratio of 0.37.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Wednesday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.26. The firm had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.20 billion. Astellas Pharma had a net margin of 4.34% and a return on equity of 19.76%. On average, research analysts forecast that Astellas Pharma will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.